source
- Fulcrum Therapeutics considers sale after FDA blocks sickle cell drug developmentFulcrum Therapeutics announced it is undertaking a strategic review that could lead to a sale after its lead sickle cell candidate, pociredir, was effectively blocked by the FDA. The agency cited…
- AbiVax shares plunge as safety concerns shadow strong ulcerative colitis trial resultsAbiVax reported Phase 3 data for its experimental therapy obefazimod in patients with moderately to severely active ulcerative colitis. Two dose levels achieved placebo‑adjusted clinical remission…